IQVIA in the news

IQVIA Holdings' stock shows strong past returns and DCF undervaluation, but earnings multiples suggest it is overvalued, creating a mixed investment outlook.

IQVIA discusses how to integrate decentralised and hybrid trial designs from the start to enhance patient access and trial efficiency.

Pharma marketers need to unify fragmented campaign data through robust identity resolution and transparent, holistic measurement to build trust and improve investment decisions.

IQVIA Holdings' stock hit a 52-week high of $260.32, fueled by strong Q2 2026 results exceeding expectations and positive analyst revisions, signaling robust performance and investor confidence.

IQVIA Holdings stock has significantly outperformed the market, driven by strong FY2026 earnings, record bookings, and an optimistic Wall Street outlook.

Mike King of IQVIA discusses how AI transforms technology decisions in life sciences, emphasizing data integration, governance, and vendor selection for long-term value and compliance.

Danske Bank A/S purchased a significant stake in IQVIA, while several other institutional investors adjusted their holdings, and IQVIA announced a $2 billion share buyback program alongside strong financial results and positive analyst outlooks.

IQVIA's AI-enabled Clinical Decision Support Tool, developed with Breakthrough T1D, won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year for improving diabetes diagnosis.

IQVIA Holdings Inc. (IQV) has shown strong financial performance, outperforming the market and raising its full-year 2026 guidance following better-than-expected FY2026 earnings.

Institutional investors are increasing their stakes in IQVIA Holdings Inc. after the company reported strong earnings, leading to a stock price increase and a share buyback announcement.

Edmond DE Rothschild Holding S.A. purchased a new position in IQVIA, while other institutional investors increased holdings, despite insider selling, as analysts raised price targets after strong earnings and a share buyback announcement.

IQVIA Holdings Inc. stock exceeded competitors' performance during a robust trading session.

IQVIA's stock hit a 52-week high supported by strong Q2 earnings, positive analyst ratings, and significant institutional investment.

Deutsche Bank AG acquired a significant stake in IQVIA Holdings Inc. during the second quarter, while the company reported strong earnings and announced a substantial share buyback program.

BlackRock Inc. bought over 14.5 million shares of IQVIA Holdings Inc., making them a significant shareholder, while IQVIA reported strong Q2 earnings and initiated a stock repurchase program.

Act Two Investors LLC invested over $30 million in IQVIA, a medical research company, alongside other institutional investors, while IQVIA's board approved a $2 billion share repurchase program.

Mitsubishi UFJ Asset Management Co. Ltd. invested $78.51 million in IQVIA, a medical research company, as other institutional investors also increased their holdings.

Danica Pension Livsforsikringsaktieselskab significantly increased its stake in IQVIA, a medical research company, while several other institutional investors also adjusted their positions, and IQVIA announced a $2 billion stock buyback plan.

IQVIA partnered with Medera to combine clinical trial capabilities with gene therapy and human cardiac tissue platforms, deepening its role in advanced drug development and leveraging AI for efficiency.

Focus Partners Advisor Solutions LLC and other institutional investors acquired new shares in IQVIA, while company insiders sold stock, amidst strong Q2 earnings and a new share repurchase plan.